Premium
N‐glycolylneuraminic acid knockout reduces erythrocyte sequestration and thromboxane elaboration in an ex vivo pig‐to‐human xenoperfusion model
Author(s) -
Cimeno Arielle,
Hassanein Wessam,
French Beth M.,
Powell Jessica M.,
Burdorf Lars,
Goloubeva Olga,
Cheng Xiangfei,
Parsell Dawn M.,
Ramsoondar Jagdeece,
Kuravi Kasinath,
Vaught Todd,
Uluer Mehmet C.,
Redding Emily,
O'Neill Natalie,
Laird Christopher,
Hershfeld Alena,
Tatarov Ivan,
Thomas Kathryn,
Ayares David,
Azimzadeh Agnes M.,
Pierson Richard N.,
Barth Rolf N.,
LaMattina John C.
Publication year - 2017
Publication title -
xenotransplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.052
H-Index - 61
eISSN - 1399-3089
pISSN - 0908-665X
DOI - 10.1111/xen.12339
Subject(s) - ex vivo , sialic acid , in vivo , chemistry , immunology , biology , microbiology and biotechnology , pharmacology , biochemistry
Background Wild‐type pigs express several carbohydrate moieties on their cell surfaces that differ from those expressed by humans. This difference in profile leads to pig tissue cell recognition of human blood cells causing sequestration, in addition to antibody‐mediated xenograft injury. One such carbohydrate is N‐glycolylneuraminic acid (Neu5Gc), a sialic acid molecule synthesized in pigs but not in humans. Here, we evaluate livers with and without Neu5Gc in an ex vivo liver xeno perfusion model. Methods Livers from pigs with an α1,3‐galactosyl transferase gene knockout (Gal TKO ) and transgenic for human membrane cofactor ( hCD 46) with (n = 5) or without (n = 7) an additional Neu5Gc gene knock out (Neu5Gc KO ) were perfused ex vivo with heparinized whole human blood. A drug regimen consisting of a histamine inhibitor, thromboxane synthase inhibitor, and a murine anti‐human GPI b‐blocking antibody fragment was given to half of the experiments in each group. Results Liver function tests ( AST and ALT ) were not significantly different between livers with and without the Neu5Gc KO . Gal TKO . hCD 46.Neu5Gc KO livers had less erythrocyte sequestration as evidenced by a higher mean hematocrit over time compared to Gal TKO . hCD 46 livers ( P = .0003). The addition of Neu5Gc KO did not ameliorate profound thrombocytopenia seen within the first 15 minutes of perfusion. TXB 2 was significantly less with the added drug regimen ( P = .006) or the presence of Neu5Gc KO ( P = .017). Conclusions The lack of Neu5Gc expression attenuated erythrocyte loss but did not prevent profound early onset thrombocytopenia or platelet activation, although TXB 2 levels were decreased in the presence of Neu5Gc KO .